Jay Olson
Stock Analyst at Oppenheimer
(3.61)
# 759
Out of 4,920 analysts
242
Total ratings
41.92%
Success rate
7.96%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNMD Mind Medicine (MindMed) | Reinstates: Outperform | $25 | $9.41 | +165.67% | 1 | Aug 4, 2025 | |
| ATAI Atai Life Sciences | Initiates: Outperform | $14 | $3.97 | +252.64% | 1 | Jul 29, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $97 → $115 | $47.48 | +142.21% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $19 → $22 | $23.45 | -6.18% | 15 | Jun 26, 2025 | |
| PRTA Prothena Corporation | Downgrades: Perform | n/a | $7.58 | - | 15 | May 27, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Outperform | $65 | $25.49 | +155.00% | 1 | May 21, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $80 → $65 | $2.95 | +2,107.13% | 5 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Maintains: Outperform | $15 → $13 | $1.49 | +772.48% | 3 | May 14, 2025 | |
| RVMD Revolution Medicines | Maintains: Outperform | $70 → $75 | $38.09 | +96.90% | 9 | May 8, 2025 | |
| IMRX Immuneering | Maintains: Outperform | $25 → $21 | $3.48 | +504.32% | 2 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $90 | $22.55 | +299.11% | 6 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $42 | $14.18 | +196.19% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $41 → $33 | $37.16 | -11.19% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $11.09 | +260.85% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $1.94 | +931.46% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $8.98 | +234.08% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $6.15 | +225.47% | 2 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $255 | $131.52 | +93.89% | 25 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $77.42 | +5.92% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $375 → $350 | $338.03 | +3.54% | 10 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $3.22 | +210.09% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $33.13 | +316.54% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.60 | +400.00% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 | $7.81 | +514.60% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $287.30 | +32.27% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $127.17 | +72.21% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $2.58 | +365.12% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $3.34 | +438.92% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.86 | +1,062.93% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $53.81 | +76.55% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.78 | +561.38% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $75 | $41.54 | +80.55% | 3 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $0.69 | +1,204.35% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | n/a | $9.82 | - | 6 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,200 → $500 | $5.00 | +9,895.60% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $7.33 | +186.49% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.57 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $17.80 | +371.91% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.10 | - | 3 | Jul 11, 2017 |
Mind Medicine (MindMed)
Aug 4, 2025
Reinstates: Outperform
Price Target: $25
Current: $9.41
Upside: +165.67%
Atai Life Sciences
Jul 29, 2025
Initiates: Outperform
Price Target: $14
Current: $3.97
Upside: +252.64%
Praxis Precision Medicines
Jul 8, 2025
Maintains: Outperform
Price Target: $97 → $115
Current: $47.48
Upside: +142.21%
ACADIA Pharmaceuticals
Jun 26, 2025
Maintains: Perform
Price Target: $19 → $22
Current: $23.45
Upside: -6.18%
Prothena Corporation
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $7.58
Upside: -
Tvardi Therapeutics
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $25.49
Upside: +155.00%
Jasper Therapeutics
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $2.95
Upside: +2,107.13%
Inovio Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $1.49
Upside: +772.48%
Revolution Medicines
May 8, 2025
Maintains: Outperform
Price Target: $70 → $75
Current: $38.09
Upside: +96.90%
Immuneering
May 7, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $3.48
Upside: +504.32%
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $22.55
Upside: +299.11%
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $14.18
Upside: +196.19%
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $37.16
Upside: -11.19%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $11.09
Upside: +260.85%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $1.94
Upside: +931.46%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $8.98
Upside: +234.08%
Dec 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $6.15
Upside: +225.47%
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $131.52
Upside: +93.89%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $77.42
Upside: +5.92%
Oct 23, 2024
Maintains: Outperform
Price Target: $375 → $350
Current: $338.03
Upside: +3.54%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $3.22
Upside: +210.09%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $33.13
Upside: +316.54%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.60
Upside: +400.00%
Aug 7, 2024
Maintains: Outperform
Price Target: $48
Current: $7.81
Upside: +514.60%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $287.30
Upside: +32.27%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $127.17
Upside: +72.21%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $2.58
Upside: +365.12%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $3.34
Upside: +438.92%
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $0.86
Upside: +1,062.93%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $53.81
Upside: +76.55%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $3.78
Upside: +561.38%
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $41.54
Upside: +80.55%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $0.69
Upside: +1,204.35%
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $9.82
Upside: -
Nov 30, 2023
Maintains: Outperform
Price Target: $1,200 → $500
Current: $5.00
Upside: +9,895.60%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $7.33
Upside: +186.49%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.57
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $17.80
Upside: +371.91%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.10
Upside: -